The New Biology of NSCLC
 |
 |
 |
 |
Keynote Lecture - Personalized Therapy in Lung Cancer: Ready for Prime Time?
|
|
|
|
LCUTT114/Video
TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical oncologists, hematologist-oncologists, radiation oncologists, fellows and other healthcare providers involved in the treatment of lung cancer.
LCUTT114/Audio
OVERVIEW OF ACTIVITY
ASHNHL16
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.
OVERVIEW OF ACTIVITY
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma
Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Multiple Myeloma
ASHMM14
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).
OVERVIEW OF ACTIVITY
Targeted Therapeutic Options in Non-Hodgkin Lymphomas
RELEVANCE Trial Design
Targeted Therapeutic Options in Non-Hodgkin Lymphomas
ECOG-E2408 Trial Design
Oncology Nursing Update Lung Cancer Edition, Issue 1, 2014
OVERVIEW OF ACTIVITY
CNS Tumor Panel and Journal Club: Clinical Investigators Provide Perspectives on Current Cases and Key Presentations and Publications
5MJCASH2014
Each year, thousands of clinicians, basic scientists and other industry professionals sojourn to major international oncology conferences, like the American Society of Hematology (ASH) annual meeting, to hone their skills, network with colleagues and learn about recent advances altering state-of-the-art management in hematologic oncology. As such, these events have become global stages where exciting science, cutting-edge concepts and practice-changing data emerge on a truly grand scale. This massive outpouring of information has enormous benefits for the hematologic oncology community, but the truth is it also creates a major challenge for practicing oncologists and hematologists.